Greg Divis is the interim CEO of Avadel Pharmaceuticals, previously the Chief Operating Officer having joined the company in 2017.  Prior to this, Greg was an Operating Partner/ Executive in Residence at Linden Capital Partners, a middle market, healthcare-focused private equity firm.  Prior to his current role, Mr. Divis served as the President and CEO of Lumara Health™, a leading specialty pharmaceutical company dedicated to woman’s healthcare. Mr. Divis has been working in the pharmaceutical industry for more than 25 years and joined Lumara Health™ in the summer of 2007 as the President of Ther-Rx Corporation, the branded pharmaceutical subsidiary of the Company. He was named permanent CEO in November 2010 while continuing to serve as President of Ther-Rx Corporation.

Mr. Divis began his career as a sales representative and has served in a variety of commercial and general management leadership roles at pharmaceutical companies such as Schering-Plough Corporation and Sanofi-Aventis both in the US and in Europe. This included direct responsibility for entire country operations, extensive business development experience, and significant commercial leadership experience for large multi-national corporations. Mr. Divis earned a Bachelor’s degree from the University of Iowa.